Form 4 for CADL Candel Therapeutics, Inc.
Accepted 2023-11-28 00:00:00 ET · period of report 2023-11-26 · accession 0001209191-23-056802 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-28 | 2023-11-26 | CADL | Amello Jason | CFO | A - Grant | $0.00 | +125.7K | 222.2K | +130% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-26 | A | A | 125,717 | $0.00 | 222,162 | D | — | — | (F1) Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. 50% of the RSUs shall vest on June 30, 2024, and the remaining 50% on December 31, 2024, in each case subject to the Reporting Person's continued service on such vesting date. |